Applied Therapeutics Shares Down 20%

Shares of Applied Therapeutics Inc. (APLT) are slipping nearly 20% despite no stock-specific news to hurt the shares.

APLT is currently trading at $14.27, down $3.51 or 19.72%, on the Nasdaq. The stock has traded between $13.58 and $29.80 in the 52-week period. The company's stock value has slipped over 35% in that time frame.

Applied Therapeutics, a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase I/II for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Follow RTT